Our Approach to Materiality

Materiality assessment

Materiality assessments are used to identify which economic, social and environmental issues are of greatest interest to both a business and its stakeholders. In 2016, we conducted a formal materiality assessment and developed a matrix reflecting the most material issues for AbbVie.

We collected and assessed inputs from a range of internal and external sources to identify and evaluate material issues. We conducted interviews with a broad cross-section of external stakeholders including global health experts, nonprofit organizations, patient groups, academics, suppliers and industry associations. In addition, we gathered insights by interviewing executives and leaders across the business. Ultimately the 25 issues most material for AbbVie were mapped.

Based on this assessment, we identified the following topics as both highly material to AbbVie and very important to stakeholders:

- Product innovation and R&D productivity
- Drug pricing, reimbursement, intellectual property and biosimilar landscape
- Product quality and security
- Transparency, ethics and compliance
- Health and well-being at all ages
- Environmental stewardship

Ongoing analysis

We recognize that material issues evolve over time. Since we conducted the materiality assessment we have used ongoing benchmarking and stakeholder engagement to ensure alignment of our responsibility priorities.

We use external frameworks such as those developed by the Dow Jones Sustainability Index, the FTSE4Good Index, CDP and the Sustainability Accounting Standards Board (SASB) to assess our areas of focus and our progress.
We also engage in ongoing dialogue with a wide variety of stakeholders. This allows us to understand our stakeholders’ evolving needs, interests and expectations of AbbVie. From these interactions, we maintain our understanding of material issues and identify best practices and additional opportunities to make a contribution.

**Patient Groups**
Patients are at the heart of everything we do. We regularly engage with patient groups to understand patient needs and to work toward common desired outcomes.

**Health Care Professionals**
We want to equip health care professionals with the means to help their patients achieve better health and wellness. We consult with clinicians and researchers to understand the challenges they and their patients face and to receive input and feedback on our priorities, strategies, products and programs. We collaborate with scientific and professional associations to advance shared public health goals.

**Payers**
We work closely with payers to ensure a shared understanding of patient and health system needs and to find sustainable ways to make our medicines accessible and affordable to patients who need them.

**Suppliers & Partners**
Suppliers and partners are an extension of our business. Our work, our success and our reputations are interconnected. Through business reviews, site visits and supplier forums, we work closely with suppliers and partners to build productive relationships and understand how we can optimize our shared enterprise.

**Employees**
The capabilities and engagement of our employees are what make us successful, and their experience in our business gives them a unique perspective. Through employee surveys, town hall meetings and informal interactions, we hear their feedback, address their questions and gather their input.

**Investors & Financial Community**
Our investors expect us to create long-term value, and we actively engage with them on an ongoing basis to hear their perspectives on our opportunities and progress.

**Governments & Policymakers**
Health care is important to all people and therefore governments and policymakers take an active interest in our work. Through an ongoing dialogue with decision-makers we can understand how best to collaborate to meet patient, community and health system needs.

**Nonprofit Organizations**
Nonprofit organizations address the needs of some of the most vulnerable populations. We value the opportunity to benefit from their unique perspective on unmet needs and to understand how AbbVie can help to address them.

Through this process the following topics have risen in importance to join those already identified in our materiality assessment.

- Equality, Diversity and Inclusion
- Talent Attraction, Retention and Development
- Community Engagement

This comprehensive and ongoing materiality assessment process is an important input to our corporate responsibility framework and activities. Our approach ensures that AbbVie’s priorities remain current and that our activities are relevant and impactful for our business, our patients, our employees and our society.